FGEN FibroGen Corporation Total Debt to Capital

FibroGen, Inc. (FGEN) attracts leading biologists through innovative developments in oncology and anemia, as confirmed by the daily price chart on GURU.Markets, where the indicator stands at 0.00. The business relies on global partnerships, yet remains vulnerable to trade restrictions and raw material logistics disruptions. The current position is further complicated by a loss of market influence and a dependence on payments from Asia.

This ratio determines the financing structure by comparing total liabilities to equity to assess the degree of credit risk and the business's financial autonomy. By analyzing the debt-to-equity trend, an investor can see the balance between borrowed capital and the resources FibroGen, Inc. (FGEN) requires to develop innovative HIF-PH inhibitors and bring unique anemia therapies to market.